394 related articles for article (PubMed ID: 27753650)
1. Efficacy and Safety of Once-Daily Controlled-Release Pregabalin for the Treatment of Patients With Postherpetic Neuralgia: A Double-Blind, Enriched Enrollment Randomized Withdrawal, Placebo-Controlled Trial.
Huffman CL; Goldenberg JN; Weintraub J; Sanin L; Driscoll J; Yang R; Chew ML; Scavone JM
Clin J Pain; 2017 Jul; 33(7):569-578. PubMed ID: 27753650
[TBL] [Abstract][Full Text] [Related]
2. Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study.
Arnold LM; Arsenault P; Huffman C; Patrick JL; Messig M; Chew ML; Sanin L; Scavone JM; Pauer L; Clair AG
Curr Med Res Opin; 2014 Oct; 30(10):2069-83. PubMed ID: 24867298
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study.
Moon DE; Lee DI; Lee SC; Song SO; Yoon DM; Yoon MH; Kim HK; Lee YW; Kim C; Lee PB
Clin Ther; 2010 Dec; 32(14):2370-85. PubMed ID: 21353106
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China.
Guan Y; Ding X; Cheng Y; Fan D; Tan L; Wang Y; Zhao Z; Hong Z; Zhou D; Pan X; Chen S; Martin A; Tang H; Cui L
Clin Ther; 2011 Feb; 33(2):159-66. PubMed ID: 21444113
[TBL] [Abstract][Full Text] [Related]
5. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial.
Gilron I; Wajsbrot D; Therrien F; Lemay J
Clin J Pain; 2011; 27(3):185-93. PubMed ID: 21178603
[TBL] [Abstract][Full Text] [Related]
6. A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Pregabalin for Postherpetic Neuralgia in a Population of Chinese Patients.
Liu Q; Chen H; Xi L; Hong Z; He L; Fu Y; Fang H; Shang N; Yan P; Fan D
Pain Pract; 2017 Jan; 17(1):62-69. PubMed ID: 26714731
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial.
Irving G; Jensen M; Cramer M; Wu J; Chiang YK; Tark M; Wallace M
Clin J Pain; 2009; 25(3):185-92. PubMed ID: 19333167
[TBL] [Abstract][Full Text] [Related]
8. Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study.
Wallace MS; Irving G; Cowles VE
Clin Drug Investig; 2010; 30(11):765-76. PubMed ID: 20818838
[TBL] [Abstract][Full Text] [Related]
9. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin.
Zin CS; Nissen LM; O'Callaghan JP; Duffull SB; Smith MT; Moore BJ
J Pain; 2010 May; 11(5):462-71. PubMed ID: 19962354
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial.
van Seventer R; Feister HA; Young JP; Stoker M; Versavel M; Rigaudy L
Curr Med Res Opin; 2006 Feb; 22(2):375-84. PubMed ID: 16466610
[TBL] [Abstract][Full Text] [Related]
11. Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Rauck RL; Irving GA; Wallace MS; Vanhove GF; Sweeney M
J Pain Symptom Manage; 2013 Aug; 46(2):219-28. PubMed ID: 23149085
[TBL] [Abstract][Full Text] [Related]
12. Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN).
Sang CN; Sathyanarayana R; Sweeney M;
Clin J Pain; 2013 Apr; 29(4):281-8. PubMed ID: 22801243
[TBL] [Abstract][Full Text] [Related]
13. Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy Using an NSAID for Other Pain Conditions: A Double-Blind Crossover Study.
Raskin P; Huffman C; Yurkewicz L; Pauer L; Scavone JM; Yang R; Parsons B
Clin J Pain; 2016 Mar; 32(3):203-10. PubMed ID: 25968451
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive use of controlled-release pregabalin in adults with treatment-resistant partial seizures: a double-blind, randomized, placebo-controlled trial.
French J; Brandt C; Friedman D; Biton V; Knapp L; Pitman V; Chew M; Dubrava S; Posner HB
Epilepsia; 2014 Aug; 55(8):1220-8. PubMed ID: 24962242
[TBL] [Abstract][Full Text] [Related]
15. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief.
Stacey BR; Barrett JA; Whalen E; Phillips KF; Rowbotham MC
J Pain; 2008 Nov; 9(11):1006-17. PubMed ID: 18640074
[TBL] [Abstract][Full Text] [Related]
16. Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial.
Raskin P; Huffman C; Toth C; Asmus MJ; Messig M; Sanchez RJ; Pauer L
Clin J Pain; 2014 May; 30(5):379-90. PubMed ID: 23887339
[TBL] [Abstract][Full Text] [Related]
17. Effect of Concomitant Pain Medications on Response to Pregabalin in Patients with Postherpetic Neuralgia or Spinal Cord Injury-Related Neuropathic Pain.
Schug SA; Parsons B; Almas M; Whalen E
Pain Physician; 2017; 20(1):E53-E63. PubMed ID: 28072797
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of carisbamate in patients with diabetic neuropathy or postherpetic neuralgia: results from 3 randomized, double-blind placebo-controlled trials.
Smith T; DiBernardo A; Shi Y; Todd MJ; Brashear HR; Ford LM
Pain Pract; 2014 Apr; 14(4):332-42. PubMed ID: 23692321
[TBL] [Abstract][Full Text] [Related]
19. The MOBILE Study-A Phase IIa Enriched Enrollment Randomized Withdrawal Trial to Assess the Analgesic Efficacy and Safety of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Patients with Peripheral Neuropathic Pain.
Bradford D; Stirling A; Ernault E; Liosatos M; Tracy K; Moseley J; Blahunka P; Smith MD
Pain Med; 2017 Dec; 18(12):2388-2400. PubMed ID: 28383710
[TBL] [Abstract][Full Text] [Related]
20. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
Rice ASC; Dworkin RH; McCarthy TD; Anand P; Bountra C; McCloud PI; Hill J; Cutter G; Kitson G; Desem N; Raff M;
Lancet; 2014 May; 383(9929):1637-1647. PubMed ID: 24507377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
